INSY Insys Therapeutics Inc.

INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7

INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7

PHOENIX, March 06, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, Mar. 7, after the U.S. financial markets close.

Following the release, Saeed Motahari, president and chief executive officer, and Andy Long, chief financial officer, will host a conference at 5:00 p.m. Eastern Time to discuss the results.

Interested parties can listen to the call live as it occurs via the company’s website, , on the Investors section’s Presentations & Events page; or by dialing 844-263-8304 (from inside the U.S.) or 213-358-0958 (from outside the U.S.) and using the Conference ID 9498523. A webcasted replay of the call will be available on the site a few hours after the event.

About INSYS

is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. The company is committed to developing medications for potentially treating anaphylaxis, epilepsy, Prader-Willi syndrome, opioid addiction and overdose, and other disease areas with a significant unmet need.

 

CONTACT:   Investor Relations & Corporate Communications
 Jackie Marcus or Chris Hodges
 Alpha IR Group
 312-445-2870
 

EN
06/03/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Insys Therapeutics Inc.

 PRESS RELEASE

FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Na...

FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose PHOENIX, July 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (OTCMKTS: INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing.  INSYS’ naloxone nasal spray is a single unit dose spray device that delive...

 PRESS RELEASE

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Mo...

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions Operations to Continue in the Ordinary Course During Court-Supervised Process PHOENIX, June 12, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS received interim approvals from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions related to the Chapter 11 petitions filed on June 10, 2019. Andrew G. Long, Chief Executive Officer of INSYS Therap...

 PRESS RELEASE

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate As...

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S. Bankruptcy Code Operations to Continue as Normal Including Payment of Employee Wages and Benefits and Continuing Programs for Customers; Vendors and Suppliers to Receive Full Payment for Goods and Services Provided Post-Filing PHOENIX, June 10, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical develo...

 PRESS RELEASE

INSYS Therapeutics Reports First Quarter 2019 Results

INSYS Therapeutics Reports First Quarter 2019 Results Company Continues to Execute Against Pipeline-Focused StrategyNew Drug Application Submitted for Proprietary Naloxone Nasal Spray FormulationCompany Provides Liquidity Update PHOENIX, May 10, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial results for its first quarter ended Mar. 31, 2019. RECENT HIGHLIGHTS Appointed Andy Long as chief executive officer; in parallel promoted A...

 PRESS RELEASE

INSYS Therapeutics Implements Leadership Changes

INSYS Therapeutics Implements Leadership Changes Andrew G. Long Appointed Chief Executive Officer PHOENIX, April 15, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company. In connection with INSYS’ lead...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch